Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades22,458
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
AZN Company
Research
AZN Company
Timeline
Share Price Information for Astrazeneca (AZN)
Last checked at -
Last checked at 
Intraday Astrazeneca Share Chart
Astrazeneca News
AstraZeneca flags positive trial data for Saphnelo as SLE treatment
(Alliance News) - AstraZeneca PLC on Tuesday said a Saphnelo self-administration Thlip-SC trial demonstrated statistically significant and clinically ...
Hutchmed savolitinib NDA for gastric cancer accepted in China
(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savo...
London's FTSE 100 closes lower in shortened Christmas Eve session
FTSE 100 down 0.2%; FTSE 250 down 0.07% *
LONDON MARKET CLOSE: FTSE fails to sparkle in tame pre-holiday trade
(Alliance News) - The FTSE 100 drifted lower on Wednesday in lacklustre trading ahead of the Christmas break, although a chunky disposal by BP brought...
LONDON MARKET OPEN: FTSE mixed in shortened Christmas Eve trade
(Alliance News) - Stock prices in London opened modestly lower on Wednesday, during a shortened trading session ahead of the Christmas holiday break.
Novo Nordisk shares jump almost 8% after US approves Wegovy pill
Novo Nordisk first to market with Wegovy pill *
AstraZeneca says lung cancer trial fails to meet survival target
(Alliance News) - AstraZeneca PLC on Monday said a phase three trial in a potential treatment for a form of non-small cell lung cancer failed to meet ...
AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial
Phase III trial involved 594 patients across 20 countries *
Follow the stocks
